Curis Gains As Blood Cancer Drug Progresses, December Readout in Focusbenzinga_article·19 hours agoCRIS+4.71%
CRIS: Emavusertib shows superior efficacy and safety in NHL, CLL, and AML, advancing in registrational trialsQuartr·2 days ago, 09:05 AMCRIS+4.71%
CRIS: Emavusertib shows strong response rates in PCNSL and advances in CLL, pending further fundingQuartr·Jul 22 at 06:15 AMCRIS+4.71%
Curis notifies press release availability on positive emavusertib updatePUBT·Jul 22 at 06:04 AMCRIS+4.71%
Curis Consents First Six Patients in TakeAim CLL Study | CRIS Stock NewsStockTitan·Jul 6 at 12:30 AMCRIS+4.71%
U.S. stock market update: Curis down 14.33%, pressured by reverse stock split and SEC announcementPrice Alert·Jul 2 at 12:32 PMCRIS+4.71%
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga_article·Jul 1 at 04:05 PMCMMB-2.86%CRIS+4.71%
Curis shares are trading lower after the company announced that its stockholders have approved a 1‑for‑20 reverse split of its common stock.benzinga_article·Jul 1 at 01:02 PMCRIS+4.71%
